Indeed, in-vitro gene therapy with lentiviral transduction of p60-BBF2H7, a transactivator of Sec23a, has been shown to compensate for mutated SEC23B in primary human erythroblasts isolated from CDA II patients [49]. The gene discussed is SEC23A; the disease is congenital dyserythropoietic anemia type 2.